Shuoshi Biotech announced that the 18th meeting of the 3rd board of directors of the company reviewed the “Proposal to Agree to the Controlling Shareholders' Request to Hold an Extraordinary Shareholders' Meeting”. The voting results were 4 votes in agreement and 5 votes against, and the bill was not passed. The board of directors did not agree to hold an extraordinary shareholders' meeting. The five opposing directors argued that there is a dispute over the validity of the document seal relating to the controlling shareholder Leung Kang Biotech, and that the lawsuit for its dissolution is currently being tried. Limited partner Leung Xilin has reported and accepted the misappropriation of funds to the public security authorities. Promoting the change of office at this stage is not conducive to the stability of corporate governance and the protection of the interests of small and medium-sized investors.

Shuoshi Biotech announced that the 18th meeting of the 3rd board of directors of the company reviewed the “Proposal to Agree to the Controlling Shareholders' Request to Hold an Extraordinary Shareholders' Meeting”. The voting results were 4 votes in agreement and 5 votes against, and the bill was not passed. The board of directors did not agree to hold an extraordinary shareholders' meeting. The five opposing directors argued that there is a dispute over the validity of the document seal relating to the controlling shareholder Leung Kang Biotech, and that the lawsuit for its dissolution is currently being tried. Limited partner Leung Xilin has reported and accepted the misappropriation of funds to the public security authorities. Promoting the change of office at this stage is not conducive to the stability of corporate governance and the protection of the interests of small and medium-sized investors.